Vestiq Pharmaceuticals, Inc. launches with agenda for rapid growth, acquires NDAs for ORAVIG® and Zuplenz® oral soluble film

Vestiq Pharmaceuticals, an emerging Specialty Pharmaceutical Company, formally announces its launch of products that began commercialization in December of 2012. Vestiq is strategically formed through a consolidation of existing U.S. and international pharmaceutical entities and industry partnerships. The Company’s headquarters are located near Research Triangle Park, N.C., and the company’s website is www.vestiqpharma.com.

“Our business model is to create a high growth pharmaceutical company through strategic acquisitions,” said Martin “Marty” G. Baum, President and CEO, Vestiq Pharmaceuticals. “Our mission is to bring innovative, effective and safe therapeutic solutions to healthcare providers and patients, to improve the quality of human life. We’re proud that unlike so many newer companies, we have our vision for the future set and began acting upon it from day one.”

Vestiq has acquired the stock of Praelia Pharmaceuticals, Inc. to serve as its branded pharmaceutical entity.

“Praelia is very excited about merging our company with Vestiq,” said Steve Lutz, CEO, Praelia Pharmaceuticals. “We felt the two companies complemented each other perfectly. Together we are positioned for tremendous success moving forward.”

Vestiq launches with completed partnerships with Vanguard Pharma, Inc. to act as its contract sales organization, resulting in an immediate national sales force, and Synopia Rx, Inc., which serves as its managed care contracting organization.

ORAVIG and Zuplenz Acquisitions

Vestiq has acquired two recently approved NDA’s ORAVIG miconazole 50mg buccal tablets from BioAlliance, Inc. and Zuplenz (ondansetron) oral soluble film from MonoSol Rx, Inc.

ORAVIG is indicated for the local treatment of oropharyngeal candidiasis (OPC) in adults.

“It is a great satisfaction for BioAlliance to have Oravig, our first product developed and registered in US, launched on the US market by our partner Vestiq. With a strong focus on the oncology supportive arena and driven by highly experience professionals, Vestiq is our partner of choice to make Oravig rapidly accessible to professionals and patients to treat their oral candidiasis,” said Judith Greciet, CEO, BioAlliance Pharma.

Vestiq has also entered into a co-promotion agreement with Women’s Choice Pharmaceuticals for Zuplenz (ondansetron) oral soluble film, in order to increase its national sales presence. Zuplenz is indicated for the prevention of postoperative, highly and moderately emetogenic cancer chemotherapy-induced, and radiotherapy-induced nausea and vomiting.

“We are impressed by Vestiq’s commitment to supportive care and we are excited to have Vestiq as our partner for Zuplenz,” said Mark Schobel, CEO, MonoSol RX.

“We are extremely excited to enter into this agreement with a quality partner such as Vestiq,” said Joe Ducharme, President and CEO of Women’s Choice Pharmaceuticals. “We believe Zuplenz fills an important niche in the anti-emetic market by offering a convenient and easy-to-administer option for patients who have trouble swallowing tablets. This opportunity is an excellent fit with WCP’s current product portfolio, and we are excited for our sales force to help deliver a new option to the physicians and patients we serve”.

Vestiq intends, through additional acquisitions, to focus on additional oncology supportive care products, women’s health, and pain management.

SynopiaRx and Vanguard Pharma Tapped for Expertise

Vestiq has partnered with SynopiaRx, who will administer managed care and third parties for the company.

“SynopiaRx is delighted to have the opportunity to partner with Vestiq,” said Steve Stefano, Managing Partner SynopiaRx. “We believe the appropriate strategy and positioning of their medicines within the Payer Markets will be an important factor in optimizing their commercial success.”

Vestiq has also completed an agreement with Vanguard Pharma, to act as their contract sales organization. Through these agreements, Vestiq immediately has sales representatives and account managers on a nationwide basis.

“We are tremendously excited about our new partnership with Vestiq,” said Kevin Danylchuck, President and General Manager, Vanguard Pharma. “With this agreement, Vanguard has the opportunity to field a highly experienced national team of speciality sales representatives yet provide Vestiq/Praelia with the flexibility and value that is integral to our business model.”